Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth
Company Boasts 51 Late-Stage Candidates
Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.
